Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 250

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Exosomal proteins as prognostic biomarkers in non‐small cell lung cancer

Open access
Sandfeld-Paulsen, B., Aggerholm-Pedersen, N., Bæk, R., Jakobsen, K.R., Meldgaard, P., Folkersen, B.H., Rasmussen, T.R., Varming, K., Jørgensen, M.M., Sorensen, B.S.·2016·Molecular Oncology

Abstract

Background: Use of exosomes as biomarkers in non‐small cell lung cancer (NSCLC) is an intriguing approach in the liquid‐biopsy era. Exosomes are nano‐sized vesicles with membrane‐bound proteins that reflect their originating cell. Prognostic biomarkers are needed to improve patient selection for optimal treatment. We here evaluate exosomes by protein phenotyping as a prognostic biomarker in NSCLC. Methods: Exosomes from plasma of 276 NSCLC patients were phenotyped using the Extracellular Vesicle Array; 49 antibodies captured the proteins on the exosomes, and a cocktail of biotin‐conjugated antibodies binding the general exosome markers CD9, CD81 and CD63 was used to visualise the captured exosomes. For each individual membrane‐bound protein, results were analysed based on presence, in a concentration‐dependent manner, and correlated to overall survival (OS). Results: The 49 proteins attached to the exosomal membrane were evaluated. NY‐ESO‐1, EGFR, PLAP, EpCam and Alix had a significant concentration‐dependent impact on inferior OS. Due to multiple testing, NY‐ESO‐1 was the only marker that maintained a significant impact on inferior survival (hazard rate (HR) 1.78 95% (1.78–2.44); p = 0.0001) after Bonferroni correction. Results were adjusted for clinico‐pathological characteristics, stage, histology, age, sex and performance status. Conclusion: We illustrate the promising aspects associated with the use of exosomal membrane‐bound proteins as a biomarker and demonstrate that they are a strong prognostic biomarker in NSCLC.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.molonc.2016.10.003

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 250

Metadata

Authors
Sandfeld-Paulsen, B., Aggerholm-Pedersen, N., Bæk, R., Jakobsen, K. R., Meldgaard, P., Folkersen, B. H., Rasmussen, T. R., Varming, K., Jørgensen, M. M., & Sorensen, B. S.
Venue
Molecular Oncology
Publisher
Wiley
Published
2016-10-21
Volume
10
Issue
10
Pages
1595-1602
ISSN
  • 1574-7891 (ISSN-L)
  • 1878-0261
OpenAlex
W2536901971
Cited by
250
References
4
FWCI
10.23
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Exosomal proteins as prognostic biomarkers in non‐small cell lung cancer. https://app.cochat.ai/papers/10.1016/j.molonc.2016.10.003
The paper
Sandfeld-Paulsen, B., Aggerholm-Pedersen, N., Bæk, R., Jakobsen, K. R., Meldgaard, P., Folkersen, B. H., Rasmussen, T. R., Varming, K., Jørgensen, M. M., & Sorensen, B. S. (2016). Exosomal proteins as prognostic biomarkers in non‐small cell lung cancer. Molecular Oncology. https://doi.org/10.1016/j.molonc.2016.10.003

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.